Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

Instagram is introducing a new tool that lets you see and control your algorithm, starting with Reels, the company announced on Wednesday. The new tool, called “Your Algorithm,” lets you view the ...

Abstract: The Floyd-Warshall algorithm, traditionally used for finding all-pairs shortest paths, faces challenges in large-scale warehouse settings due to its high time complexity. This paper proposed ...

Two boxing legends are set to go head-to-head in what could be one of the most intriguing bouts of all time. Mike Tyson, one of the greatest heavyweight boxers ever, and Floyd Mayweather, one of the ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Abstract: In the testing of chips, defect diagnostics in X-ray images of packaging chips is mainly performed by humans, which is time-consuming and inefficient. To overcome the abovementioned problems ...

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...